Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24828555 | 0.86 | GAA (0.36) | MAPTKCNH2ACHEKMT2AMEN1 | |
| SCHEMBL24828355 | 0.82 | HDAC6 (0.34) | MAPTKCNH2ACHEKMT2AMEN1 | |
| SCHEMBL24828668 | 0.72 | CSF1R (0.35) | MAPTKCNH2ACHEKMT2AMEN1 | |
| SCHEMBL24828484 | 0.71 | KCNH2 (0.34) | KCNH2POLBLMNAGAA | |
| SCHEMBL30240839 | 0.69 | — | — | |
| SCHEMBL2756556 | 0.68 | — | — | |
| SCHEMBL24828534 | 0.67 | ALDH1A1 (0.37) | MAPTKCNH2ACHEKMT2AMEN1 | |
| SCHEMBL12092593 | 0.66 | MAPT (0.37) | MAPTKCNH2ACHEKMT2AALDH1A1 | |
| SCHEMBL24828535 | 0.66 | HSD17B10 (0.51) | MAPTKCNH2KMT2AMEN1POLB | |
| SCHEMBL22509544 | 0.66 | MAPT (0.49) | MAPTKMT2AMEN1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | MAPT 3454/4885KCNH2 3473/4885ACHE 2098/4885 |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | MAPT 3687/4885KCNH2 3333/4885ACHE 2168/4885 |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | MAPT 3687/4885KCNH2 3333/4885ACHE 2168/4885 |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | MAPT 3454/4885KCNH2 3473/4885ACHE 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.